Open an account

Becton Dickinson and

BDX · NYSE

$193.80+$3.06 (+1.60%)TodayMarket closed ·
Prev close $190.74

About BDX

Becton, Dickinson & Co. is a global medical technology company, which engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. The company is headquartered in Franklin Lakes, New Jersey and currently employs 72,000 full-time employees. The firm is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. The company operates through five segments: BD Medical Essentials, BD Connected Care, BD BioPharma Systems, BD Interventional, and BD Life Sciences. BD Medical Essentials segment includes medication delivery solutions and specimen management. BD Connected Care segment includes medication management solutions and advanced patient monitoring. BD Interventional segment includes urology and critical care, peripheral intervention and surgery. Its Life Sciences segment includes diagnostic solutions and biosciences.

Employees
72,000
Headquarters
Franklin Lakes, New Jersey
Listed
Sep 25, 1963
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
bd.com

BDX key statistics

Market cap
52.79B
Price-earnings ratio
57.45
Dividend yield
2.23%
Average volume
1.53M
Volume
1.08M
Open price
$192.78
High today
$193.85
Low today
$191.35
52 Week high
$195.99
52 Week low
$127.59

Becton Dickinson and (BDX) at a glance

As of Oct 20, 2026, Becton Dickinson and (BDX) shares are priced at $193.80, giving the company a market cap of 52.79B, a price-to-earnings ratio of 57.45 and a dividend yield of 2.23%.

Today the stock has traded between $191.35 and $193.85. The current price is 1.3% above the day's low and 0.0% below its high.

Volume so far is 1.08M shares, below the average of 1.53M shares a day.

Over the past year Becton Dickinson and has ranged from $127.59 to $195.99, and now sits 97% of the way up that range.

Becton Dickinson and met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported $3.23 per share against an estimate of $3.17.

The average analyst price target is $202.98, 4.7% above the current price, from 16 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

44%of 16 analyst ratings say Buy
  • Buy43.8%
  • Hold50.0%
  • Sell6.3%
Price target · 16 analystsAvg $202.98
Low
$171.70
Now
$193.80
High
$237.31

BDX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 4.6% on average.

  1. Q3 FY24: reported $3.50 per share against an estimate of $3.34
  2. Q4 FY24: reported $3.81 per share against an estimate of $3.81
  3. Q1 FY25: reported $3.43 per share against an estimate of $3.01
  4. Q2 FY25: reported $3.35 per share against an estimate of $3.31
  5. Q3 FY25: reported $3.68 per share against an estimate of $3.44
  6. Q4 FY25: reported $3.96 per share against an estimate of $3.96
  7. Q1 FY26: reported $2.90 per share against an estimate of $2.80
  8. Q2 FY26: reported $3.23 per share against an estimate of $3.17

BDX news

  • Press releasePRNewswire

    BD to Announce Financial Results for its Fourth Quarter and Full Year of Fiscal 2026

  • Press releasePRNewswire

    BD and Global Health Leaders Call for Accelerated Maternal Life Saving Measures Worldwide

  • Press releasePRNewswire

    BD Strengthens Leadership in Peripheral Vascular Innovation with Positive AGILITY Trial Results

  • Vandana Singh

    Becton Dickinson Commits Massive $19 Billion To Expand Domestic Medical Manufacturing

  • Press releasePRNewswire

    BD Celebrates 65 Years of Manufacturing, Innovation and Community Partnership in Canaan

  • Press releasePRNewswire

    BD Appoints Ferass Abuzaina as Worldwide President of Surgery

  • Press releasePRNewswire

    BD and U.S. Government Launch Landmark Partnership to Expand U.S. Manufacturing and Strengthen America's Healthcare Resilience

  • Namrata Sen

    Trump Says Becton Dickinson to Invest $3 Billion in US Manufacturing as 'Strong' Medical Device Tariffs Loom by Year-End

Similar companies

Companies in the same industry as Becton Dickinson and

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.